Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496366
Status:
TERMINATED
Last Update Posted:
2017-03-21
First Post:
2007-07-03
Brief Title:
Capecitabine Xeloda and Lapatinib Tykerb as First-line Therapy in HER2Neu-positive Breast Cancer
Sponsor:
Rutgers The State University of New Jersey
Organization:
Rutgers The State University of New Jersey
Organization Data
Organization:
Rutgers The State University of New Jersey
Class:
OTHER
Study ID:
040608
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Rutgers The State University of New Jersey
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |
| Rutgers Cancer Institute of New Jersey | OTHER |